125 related articles for article (PubMed ID: 38796112)
21. Discovery of Bispecific Lead Compounds from
Kumar S; El-Kafrawy SA; Bharadwaj S; Maitra SS; Alandijany TA; Faizo AA; Khateb AM; Dwivedi VD; Azhar EI
Molecules; 2022 Apr; 27(8):. PubMed ID: 35458761
[TBL] [Abstract][Full Text] [Related]
22. Identification of Montelukast as flavivirus NS2B-NS3 protease inhibitor by inverse virtual screening and experimental validation.
Jiang H; Zhang Y; Wu Y; Cheng J; Feng S; Wang J; Wang X; Cheng M
Biochem Biophys Res Commun; 2022 May; 606():87-93. PubMed ID: 35339757
[TBL] [Abstract][Full Text] [Related]
23. Flavonoids from Pterogyne nitens as Zika virus NS2B-NS3 protease inhibitors.
Lima CS; Mottin M; de Assis LR; Mesquita NCMR; Sousa BKP; Coimbra LD; Santos KB; Zorn KM; Guido RVC; Ekins S; Marques RE; Proença-Modena JL; Oliva G; Andrade CH; Regasini LO
Bioorg Chem; 2021 Apr; 109():104719. PubMed ID: 33636437
[TBL] [Abstract][Full Text] [Related]
24. Evaluating Known Zika Virus NS2B-NS3 Protease Inhibitor Scaffolds via In Silico Screening and Biochemical Assays.
Santos LH; Rocha REO; Dias DL; Ribeiro BMRM; Serafim MSM; Abrahão JS; Ferreira RS
Pharmaceuticals (Basel); 2023 Sep; 16(9):. PubMed ID: 37765127
[TBL] [Abstract][Full Text] [Related]
25. Investigating into the molecular interactions of flavonoids targeting NS2B-NS3 protease from ZIKA virus through
Yadav R; Selvaraj C; Aarthy M; Kumar P; Kumar A; Singh SK; Giri R
J Biomol Struct Dyn; 2021 Jan; 39(1):272-284. PubMed ID: 31920173
[TBL] [Abstract][Full Text] [Related]
26. Existing drugs as broad-spectrum and potent inhibitors for Zika virus by targeting NS2B-NS3 interaction.
Li Z; Brecher M; Deng YQ; Zhang J; Sakamuru S; Liu B; Huang R; Koetzner CA; Allen CA; Jones SA; Chen H; Zhang NN; Tian M; Gao F; Lin Q; Banavali N; Zhou J; Boles N; Xia M; Kramer LD; Qin CF; Li H
Cell Res; 2017 Aug; 27(8):1046-1064. PubMed ID: 28685770
[TBL] [Abstract][Full Text] [Related]
27. Crystallographic fragment screening delivers diverse chemical scaffolds for Zika virus NS2B-NS3 protease inhibitor development.
Ni X; Godoy AS; Marples PG; Fairhead M; Balcomb BH; Ferla MP; Tomlinson CWE; Wang S; Giroud C; Aschenbrenner JC; Lithgo RM; Winokan M; Chandran AV; Thompson W; Xavier MA; Williams EP; Walsh M; Fearon D; Koekemoer L; von Delft F
bioRxiv; 2024 Apr; ():. PubMed ID: 38746305
[TBL] [Abstract][Full Text] [Related]
28. Evaluation of anti-Zika virus activities of broad-spectrum antivirals and NIH clinical collection compounds using a cell-based, high-throughput screen assay.
Adcock RS; Chu YK; Golden JE; Chung DH
Antiviral Res; 2017 Feb; 138():47-56. PubMed ID: 27919709
[TBL] [Abstract][Full Text] [Related]
29. The Structure of the Zika Virus Protease, NS2B/NS3
Hilgenfeld R; Lei J; Zhang L
Adv Exp Med Biol; 2018; 1062():131-145. PubMed ID: 29845530
[TBL] [Abstract][Full Text] [Related]
30. Crystal structure of unlinked NS2B-NS3 protease from Zika virus.
Zhang Z; Li Y; Loh YR; Phoo WW; Hung AW; Kang C; Luo D
Science; 2016 Dec; 354(6319):1597-1600. PubMed ID: 27940580
[TBL] [Abstract][Full Text] [Related]
31. Inhibitory effect of flavonoids against NS2B-NS3 protease of ZIKA virus and their structure activity relationship.
Lim HJ; Nguyen TT; Kim NM; Park JS; Jang TS; Kim D
Biotechnol Lett; 2017 Mar; 39(3):415-421. PubMed ID: 27885509
[TBL] [Abstract][Full Text] [Related]
32. Allosteric Inhibitors of Zika Virus NS2B-NS3 Protease Targeting Protease in "Super-Open" Conformation.
Meewan I; Shiryaev SA; Kattoula J; Huang CT; Lin V; Chuang CH; Terskikh AV; Abagyan R
Viruses; 2023 Apr; 15(5):. PubMed ID: 37243192
[TBL] [Abstract][Full Text] [Related]
33. The Inhibition of NS2B/NS3 Protease: A New Therapeutic Opportunity to Treat Dengue and Zika Virus Infection.
Starvaggi J; Previti S; Zappalà M; Ettari R
Int J Mol Sci; 2024 Apr; 25(8):. PubMed ID: 38673962
[TBL] [Abstract][Full Text] [Related]
34. Identification of Zika Virus NS2B-NS3 Protease Inhibitors by Structure-Based Virtual Screening and Drug Repurposing Approaches.
Santos FRS; Nunes DAF; Lima WG; Davyt D; Santos LL; Taranto AG; M S Ferreira J
J Chem Inf Model; 2020 Feb; 60(2):731-737. PubMed ID: 31850756
[TBL] [Abstract][Full Text] [Related]
35. Antiviral activity of the FDA-approved drug candesartan cilexetil against Zika virus infection.
Loe MWC; Lee RCH; Chu JJH
Antiviral Res; 2019 Dec; 172():104637. PubMed ID: 31669333
[TBL] [Abstract][Full Text] [Related]
36. Generation of A Stable GFP-reporter Zika Virus System for High-throughput Screening of Zika Virus Inhibitors.
Zhang JW; Wang H; Liu J; Ma L; Hua RH; Bu ZG
Virol Sin; 2021 Jun; 36(3):476-489. PubMed ID: 33231855
[TBL] [Abstract][Full Text] [Related]
37. Analysis of cellular proteome changes in response to ZIKV NS2B-NS3 protease expression.
Tangsongcharoen C; Roytrakul S; Smith DR
Biochim Biophys Acta Proteins Proteom; 2019 Feb; 1867(2):89-97. PubMed ID: 30391636
[TBL] [Abstract][Full Text] [Related]
38. A conformational switch high-throughput screening assay and allosteric inhibition of the flavivirus NS2B-NS3 protease.
Brecher M; Li Z; Liu B; Zhang J; Koetzner CA; Alifarag A; Jones SA; Lin Q; Kramer LD; Li H
PLoS Pathog; 2017 May; 13(5):e1006411. PubMed ID: 28542603
[TBL] [Abstract][Full Text] [Related]
39. Advances in Computational Methods to Discover New NS2B-NS3 Inhibitors Useful Against Dengue and Zika Viruses.
Dos Santos Nascimento IJ; da Silva Rodrigues ÉE; da Silva MF; de Araújo-Júnior JX; de Moura RO
Curr Top Med Chem; 2022; 22(29):2435-2462. PubMed ID: 36415099
[TBL] [Abstract][Full Text] [Related]
40.
Nitsche C; Passioura T; Varava P; Mahawaththa MC; Leuthold MM; Klein CD; Suga H; Otting G
ACS Med Chem Lett; 2019 Feb; 10(2):168-174. PubMed ID: 30783498
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
